|Acceleron Speaker:||John Knopf, Ph.D., Chief Executive Officer of Acceleron|
|Date:||February 12, 2014|
|Time:||2:15 PM (EST)|
|Location:||Waldorf Astoria Hotel|
I spent the weekend with thousands of blood disease researchers. This is what happened.
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate